Latest Financial Turnaround News

NAOS EX-50 Opportunities Company Limited has initiated an on-market buy-back program targeting up to 4.58 million shares, representing 10% of its issued capital, to run from June 2026 through to June 2027.

Ryman Healthcare reported a substantial reduction in net loss for FY26 alongside its first positive free cash flow in over a decade, driven by operational improvements, refinancing, and land divestments.

L1 Long Short Fund Limited (ASX:LSF) has declared a fully franked 3.7 cent dividend, continuing a trend of rising payouts amid a standout 44.7% net return over the past year, significantly outperforming the ASX200AI benchmark.

ReadCloud announces CEO Andrew Skelton’s departure after three years of operational overhaul and financial turnaround, appointing CFO Luke Murphy as interim CEO amid strong growth momentum.

Paladin Energy Ltd (ASX:PDN) swung to a quarterly profit with US$8.4 million gross profit and bolstered its balance sheet through a A$400 million equity raise, positioning itself for expansion in uranium production and development.

Almonty Industries reported a 221% jump in Q1 2026 revenue to CAD 25.4 million, driven by soaring tungsten prices and ramp-up at its Sangdong Mine, while net loss narrowed to CAD 5.3 million amid strong operational cash flow.

EDU Holdings delivered a transformational FY25 with nearly doubled revenue and a debt-free balance sheet, driven by strong growth in its higher education arm Ikon. The company started FY26 on a solid footing despite regulatory headwinds.

Motio Ltd has marked a turning point with its first net profit, record sales activity, and a 13% increase in forward revenue, signaling a shift to scalable growth.

Bourns, Inc. has crossed the 90% acceptance threshold in its takeover of Rakon, making the offer unconditional and triggering compulsory acquisition rights and a planned delisting from NZX.

Chalice Mining has bolstered its leadership and financing strategy while advancing a Feasibility Study for its Gonneville palladium-nickel-copper project, amid improving market conditions and promising exploration results.

Starpharma has confirmed FDA alignment for its DEP® HER2 first-in-human phase 1 trial, with preparations underway for a mid-2026 start. The biotech also progressed strategic partnerships, published promising data with Genentech, and reported a $14.1 million cash balance alongside rising Viraleze™ sales.

29Metals has delivered strong final drill results from its 2025 program at Golden Grove, revealing high-grade copper and zinc intercepts that promise to boost mineral resources and mine flexibility. The company plans a significant exploration budget increase for 2026 to capitalize on this momentum.